Cargando…
Topical cenegermin associated ocular surface and contact lens drug precipitate deposit formation
PURPOSE: To report for the first time drug precipitate deposit formation on both the ocular surface and bandage contact lens (BCL) of a patient treated with topical cenegermin. OBSERVATIONS: A patient suffering from stage III neurotrophic keratitis developed extensive ocular surface and BCL deposits...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133754/ https://www.ncbi.nlm.nih.gov/pubmed/35647393 http://dx.doi.org/10.1016/j.ajoc.2022.101584 |
Sumario: | PURPOSE: To report for the first time drug precipitate deposit formation on both the ocular surface and bandage contact lens (BCL) of a patient treated with topical cenegermin. OBSERVATIONS: A patient suffering from stage III neurotrophic keratitis developed extensive ocular surface and BCL deposits over the eight week course of her topical cenegermin therapy. The ocular surface deposits were weakly adherent, detaching and clearing from the cornea within minutes of BCL removal. They reappeared rapidly and repeatedly however after each of five BCL exchanges. Symptom wise, the patient was unaware of their presence. Of historical note, this patient: (1) developed BCL ciprofloxacin deposits while undergoing a traditional neurotrophic keratitis treatment regimen, (2) did not develop corneal drug precipitate deposits within the placebo arm of the cenegermin clinical trial (vehicle only without cenegermin or BCL), and (3) did not develop corneal deposits with a latter BCL-free cenegermin treatment course. CONCLUSIONS AND IMPORTANCE: Topical cenegermin can produce extensive drug precipitate deposits on both the ocular surface and contact lens when used in conjunction with a bandage contact lens. Such deposits: (1) may represent an esthetic issue only as at least in our patient they were not symptom provoking, questionably interfered with the clinical course of the cenegermin therapy and did not require drug cessation, (2) may implicate both contact lenses and high frequency drug application as previously unidentified but formal risk factors for drug precipitate deposit formation, and (3) may act as a time-release medication reservoir enhancing drug delivery and long-term treatment efficacy. |
---|